APPLICATION OF PHARMACOGENOMICS IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER - PHARMACOGENOMICS IN THE ELDERLY

• Conditions: ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER; MedDRA version: 6.1Level: HLTClassification code 10010040

• Registration Number: EUCTR2006-004016-40-IT
• Lead Sponsor: AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-07-03
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

CYTOLOGICALLY OR HISTOLOGICALLY DIAGNOSED METASTATIC COLORECTAL CANCER BIDEMENSIONALLY EVALUABLE DISEASE METASTATIC DISEASE ECOG LESS OR EQUAL TO 2 AGE 70 OR OLDER NO PREVIOUS CHEMOTHERAPY TREATMENT FOR METASTATIC DISEASE WRITTEN INFORMED CONSENT GOOD HEMATOLOGICAL, LIVER AND RENAL FUNCTIONS
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

PREVIOUS DIAGNOSIS OF TUMOUR OTHER THAN BASAL SKIN CARCINOMA OR IN SITU CANCER OF THE UTERINE CERVIX METAL ILLNESS SYMPTOMATIC CNS METASTASES INFLAMMATORY BOWEL DISEASE SERIOUS ORGAN FAILURE

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ACTIVITY OF CHEMOTHERAPY;Secondary Objective: TOXICITY OF CHEMOTHERAPY;Primary end point(s): RESPONSE RATE